Jotin Marango - Jan 3, 2023 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
CFO & Head of Corp. Dev.
Signature
/s/ Mark Manfredi, as Attorney-in-Fact for Jotin Marango
Stock symbol
IKNA
Transactions as of
Jan 3, 2023
Transactions value $
$0
Form type
4
Date filed
1/5/2023, 03:15 PM
Previous filing
Apr 25, 2022
Next filing
Feb 2, 2024

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +105K $0.00 105K Jan 3, 2023 Common Stock 105K $2.62 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on January 1, 2024, with the remainder vesting in 36 substantially equal monthly installments thereafter.